Emerging literature, in which it is shown that hallmarks of AD can link to T2DM, and GLP-1 can reduce Aβ-peptide levels in the brain, encourage an adventurous thinking: is GLP-1 a new hope for the therapy of AD? This evidence concerns the gene GCG and Alzheimer disease.